STUDY PERIOD
Start date: September 6, 2022
End date: June 2025
STUDY INFORMATION
Indication: This study is developed to evaluate the efficacy of Xxxx compared to placebo for the treatment of agitation associated with Alzheimer’s disease.
Frequency of Visit:
Screening Visit: 1
In Person Visit: 6
STUDY CRITERIA
Age: 65 to 90 years old
Gender: Both
